Indeed, as already mentioned, the identification of HER2-low expression on locoregional recurrences or distant metastases in patients with originally HER2-0 primary breast cancer may expand patients’ therapeutic scenario by offering the opportunity to access ongoing clinical trials testing anti-HER2 ADCs in this breast cancer subgroup. The gene discussed is ERBB2; the disease is breast carcinoma.